EMA Targets Consistency In Trials For Idiopathic Pulmonary Fibrosis Drugs

 
• By Vibha Sharma
  
Doctor holding book about Idiopathic Pulmonary Fibrosis IPF.
EMA aims to unify scientific and regulatory perspectives on IPF drug development (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Pink Sheet